Literature DB >> 16721605

[Fresh plasma and concentrates of clotting factors for therapy of perioperative coagulopathy: what is known?].

B Heindl1, M Spannagl.   

Abstract

Acquired, perioperative coagulopathy often develops due to acute bleeding. In the case of primarily healthy patients with normal bone marrow and liver functions, a lack of coagulation factors initiates coagulopathy before secondary thrombopenia arises. Replacement of coagulation factors can be performed by infusion of fresh plasma (single donor or pooled plasma) or concentrates of clotting factors. Fresh plasma as well as concentrates of clotting factors available in German-speaking countries are of high quality and fulfil all safety standards. Undesirable side-effects due to transmission of infections and immunological reactions are--in all probability--more uncommon for virus-inactivated plasma and clotting factors than for single donor plasma. In contrast, thromboembolic complications are unlikely when using fresh frozen plasma, because it contains a balanced ratio of pro-coagulatory and anti-coagulatory factors. For virus-inactivated pooled plasma and concentrates of clotting factors, sporadic reports of thromboembolic events have been published. Concentrates of clotting factors can be stored easily and are rapidly prepared for use. In contrast, fresh frozen plasma has to be thawed before application leading to a significant delay in the schedule. During activated hemostasis, the half-life of clotting factors is significantly reduced in comparison to a stable physiological situation. In the case of perioperative coagulopathy higher dosages of fresh plasma and clotting factors than those recommended in published guidelines are often necessary for successful treatment. When using fresh plasma for coagulation therapy the resulting volume load must be considered. In conclusion, a modern concept of perioperative coagulation management should include fresh plasma as well as concentrates of clotting factors. The anesthetist should be familiar with the available components and be able to consider and adapt them to the individual situation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721605     DOI: 10.1007/s00101-006-1038-z

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  42 in total

Review 1.  The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.

Authors:  E Tabor
Journal:  Transfusion       Date:  1999 Nov-Dec       Impact factor: 3.157

2.  [Report on Notifications pursuant to Section 21 German Transfusion Act for 2001 and 2002].

Authors:  B Haschberger; A Waterkamp; M Heiden; R Seitz
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2005-01       Impact factor: 1.513

3.  Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.

Authors:  Kenneth David Boffard; Bruno Riou; Brian Warren; Philip Iau Tsau Choong; Sandro Rizoli; Rolf Rossaint; Mads Axelsen; Yoram Kluger
Journal:  J Trauma       Date:  2005-07

Review 4.  A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients.

Authors:  Jeffrey F Barletta; Christine L Ahrens; James G Tyburski; Robert F Wilson
Journal:  J Trauma       Date:  2005-03

5.  Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates.

Authors:  S T Hiippala; G J Myllylä; E M Vahtera
Journal:  Anesth Analg       Date:  1995-08       Impact factor: 5.108

Review 6.  Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials.

Authors:  S J Stanworth; S J Brunskill; C J Hyde; D B L McClelland; M F Murphy
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

7.  Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study.

Authors:  Rüdiger Gerlach; Fabian Tölle; Andreas Raabe; Michael Zimmermann; Annelie Siegemund; Volker Seifert
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

Review 8.  Massive transfusion and coagulopathy: pathophysiology and implications for clinical management.

Authors:  Jean-François Hardy; Philippe De Moerloose; Marc Samama
Journal:  Can J Anaesth       Date:  2004-04       Impact factor: 5.063

9.  The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.

Authors:  G B Schreiber; M P Busch; S H Kleinman; J J Korelitz
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

10.  Allergic transfusion reactions: an evaluation of 273 consecutive reactions.

Authors:  Ronald E Domen; Gerald A Hoeltge
Journal:  Arch Pathol Lab Med       Date:  2003-03       Impact factor: 5.534

View more
  1 in total

Review 1.  [Coagulation management of severe surgical bleeding].

Authors:  B Heindl; P Biberthaler
Journal:  Unfallchirurg       Date:  2008-08       Impact factor: 1.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.